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The prevalence of adult obesity in the United 
States has risen dramatically over the last three 
decades from 14.5% (Flegal et al. 1998) to 
over 33% (Flegal et al. 2010). Medical costs of 
obesity are estimated to be between $147 and 
$168 billion per year in the United States and 
account for up to 16.5% of medical care costs 
(Cai et al. 2010; Cawley and Meyerhoefer 
2010; Finkelstein et al. 2009). Childhood rates 
of obesity are rising in the United States (Wang 
et al. 2011) and in many other countries 
(Wang and Lobstein 2006). Analysis of trends 
from 1980 to 2008 also show an increase in 
body mass index (BMI) (Finucane et al. 2011) 
and diabetes (Danaei et al. 2011) in most geo-
graphic areas surveyed world-wide. The origins 
of the global obesity and diabetes epidemics are 
multifaceted, with growing evidence that mul-
tiple environmental factors contribute to their 
development. This is exemplified by emerging 
evidence of the role of gut microbial ecology in 
obesity and type 1 and type 2 diabetes (Musso 
et al. 2011; Qin et al. 2010), as well as evi-
dence from human studies and animal models 
that environmental chemicals may contribute 
to the development of these diseases (Baillie-
Hamilton 2002; Carpenter 2008; Casals-Casas 
and Desvergne 2011; Grün 2010; Heindel 
and vom Saal 2009; La Merrill and Birnbaum 
2011; Newbold et al. 2008). While inter-
individual variability in the gut microbiome 
affects the metabolism of pharmaceuticals 
(Clayton et al. 2009) and some environmental 
toxins (Dean and Ma 2007), the impact of 
gut ecology on the absorption, distribution, 
metabolism, and excretion (ADME) of xeno-
biotics, including obesogenic and diabetogenic 
chemicals, has received little to no attention. 
We review the scientific evidence that inde-
pendently links gut ecology and environmental 
chemicals to obesity and diabetes, providing a 
framework for suggesting how these environ-
mental factors may interact with these diseases, 
and identify future research needs to further 
our understanding of these relationships.
The Gut Microbiome and 
Obesity
Gut microbes outnumber human cells by 
a factor of 10, yet we know surprising little 
about many of these organisms. The meta-
genomic sequencing of the human microbiome 
reveals that there are 3.3 million nonredundant 
genes, with over 99% of the genes being of 
bacterial origin (Qin et al. 2010). This gene set 
is 150-times larger than the human genome. 
Although certain microbial species appear to 
be shared by groups of individuals (Arumugam 
et al. 2011), with > 50 species shared by 90% 
of the individuals studied, considerable varia-
tion occurs both in the types of microbes and 
in the diversity of microbial functional genes 
found between individuals (Qin et al. 2010). 
The notion of a conserved core of functional 
genes in the microbiome has been supported 
by studies in monozygote and dizygote twin 
pairs, though major differences in the abun-
dance of microbes at the phylum level were 
observed in the microbiome of obese com-
pared with lean twins (Turnbaugh and Gordon 
2009; Turnbaugh et al. 2009a). No relation-
ship between specific phyla and obesity has 
been found in a more recent study, although 
significant associations between obesity and 
inferred microbial metabolic activities such 
as energy harvesting and osmolyte produc-
tion (based on the presence of genes predicted 
to encode specific enzymatic activities) were 
found (Arumugam et al. 2011). This is con-
sistent with the observations of Calvani et al. 
(2010), who detected differences in the levels 
of microbial metabolites in the urine of obese 
compared with lean individuals.
The first suggestion that changes in adipos-
ity may influence gut micro  biota was made 
in a study of patients undergoing intestinal 
bypass (Bjorneklett et al. 1981). More recently, 
bariatric surgery has been shown to alter gut 
ecology (Furet et al. 2010; Zhang et al. 2009) 
and improve glycemic control in type 2 diabet-
ics (Ahima and Sabri 2011; Meijer et al. 2011). 
The mechanisms by which bariatric surgery 
corrects hyper  insulin  emia are unknown (Reed 
et al. 2011; Tam et al. 2011), and information 
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on the duration of this effect is not available 
(Schauer and Rubino 2011). Although it is not 
known whether the changes in microbial popu-
lations observed in patients after bypass surgery 
are directly related to changes in diabetes sta-
tus, some studies suggest changes in bacterial 
populations may be related to obesity. Changes 
in specific bacterial populations after bariat-
ric surgery include a reduction in methano-
genic Archaea (Furet et al. 2010; Zhang et al. 
2009). Zhang et al. (2009) hypothesized that 
in obese patients, methanogens could acceler-
ate the fermentation of plant polysaccharides 
by lowering hydrogen gas production during 
fermentation, leading to higher acetate produc-
tion and increased energy harvesting; however, 
that work was based on an extremely small 
sample size. Others have suggested that genetic 
factors may play an important role in deter-
mining the levels of gut methanogens (Hansen 
et al. 2011).
Experiments with germ-free or antibiotic-
treated animals have yielded conflicting evi-
dence regarding a role for gut microbes in 
the development of obesity. In some stud-
ies, germ-free mice demonstrated resistance 
to diet-induced obesity when fed a Western-
type high sugar and fat diet (Backhed et al. 
2004, 2007), whereas a more recent study 
using a different mouse line (C3H) found 
the opposite effect (Fleissner et al. 2010). In 
one mouse model, major differences were 
observed in the proportion of the different 
bacterial phyla in genetically obese mice and 
lean mice. Genetically obese ob/ob mice 
had a 50% reduction in the abundance of 
Bacteroidetes, and a proportional increase in 
Firmicutes (Ley et al. 2005). A meta  genomic 
analysis revealed that the microbiome of obese 
mice had a higher percentage of genes associ-
ated with energy extraction than that of lean 
mice (Turnbaugh et al. 2006). Further work 
in the ob/ob mouse model demonstrated that 
this trait of increased energy extraction was 
transferable: weight gain and total body fat 
was higher in germ-free mice that received 
gut micro  biota from obese mice than from 
lean mice. These differences were observed 
even though food consumption was the same 
(Turnbaugh et al. 2006).
In addition to their role in energy har-
vesting in the gut, micro  biota may also affect 
obesity and diabetes risk via several other 
mechanisms including regulation of fat storage 
(Backhed et al. 2004), metabolic endotoxemia-
induced inflammation (Cani and Delzenne 
2007; Cani et al. 2008), and levels of satiety 
factors such as glucagon-like peptides and lep-
tin (Cani et al. 2009; Ravussin et al. 2011; 
Sanz et al. 2010). For instance, C57BL/6J 
wild-type mice raised from birth with con-
ventional gut micro  biota had suppressed levels 
of fasting-induced adipocyte factor (FIAF) 
and a 42% higher body weight compared 
with germ-free mice. The broader relevance 
of this observation is unclear, since no differ-
ences were found in circulating FIAF levels 
of conventional C3H mice fed a Western or 
high-fat diet as compared with germ-free mice 
(Fleissner et al. 2010). Gut epithelial FIAF 
is a lipoprotein lipase inhibitor (LPL) and 
repressing its expression increases LPL activity 
and the storage of triglycerides in adipocytes 
(Backhed et al. 2004).
The metabolic inflammation hypothesis 
is based on the observation that mice fed a 
high-fat diet show changes in micro  biota asso-
ciated with increased intestinal permeability 
and go on to develop metabolic endotoxemia 
and inflammation. In ob/ob mice, gut micro-
biota composition affects plasma levels of 
endotoxin, presumably through altered gut 
perme  ability, which then leads to endotox-
emia, inflammation, and metabolic changes 
that may influence the risk of obesity and dia-
betes (Cani et al. 2008). Cani et al. (2009) 
observed that prebiotics in humans can influ-
ence gut microbiota, which in turn affect the 
levels of gut satiety factors including glucagon-
like peptide 1 and peptide YY. Obese-mouse 
studies characterizing diet and weight loss, and 
human studies characterizing how microbial 
communities are affected by diet, suggest com-
plex interactions exist between diet, adiposity, 
gut micro  biota, satiety hormones levels, and 
inflammation (Jumpertz et al. 2011; Muegge 
et al. 2011; Ravussin et al. 2011; Turnbaugh 
et al. 2009b, 2010).
Host genetic-gut ecology links may also 
affect immune function and the development 
of the suite of changes linked with metabolic 
syndrome (Vijay-Kumar et al. 2010). Mice 
lacking Toll-like receptor 5 (TLR5), which is 
important in immune system recognition of 
bacterial antigens in the colon, are hyperphagic 
with increased food consumption resulting in 
hyperlipidemia, hypertension, insulin resis-
tance, and increased adipocity. Transferring 
gut micro  biota from these TLR5 knock out 
mice to germ-free wild-type mice also resulted 
in hyperphagia and many of the same symp-
toms of metabolic syndrome. Unlike ob/ob 
mice that demonstrated phylum-level differ-
ences in micro  biota, the TLR5 knock out and 
wild-type mice had similar proportions 
of Bacteroidetes and Firmicutes. However, 
marked differences in certain bacterial spe-
cies in the TLR5 knock out mice were noted 
compared with wild-type mice. Surprisingly, 
Letran et al. (2011) did not observe basal 
inflammation or other metabolic changes in 
TLR5 knock out mice, although they did note 
a reduction in flagellin-specific CD4 T cells 
following Salmonella infection. The discrep-
ancy between these reports, which used geneti-
cally identical mice, was suggested to lie in the 
different micro  biota colonizing the mice at the 
different facilities. Thus, despite the apparently 
different outcome, these reports illustrate the 
importance of the gut micro  biota and its com-
plex interaction with the immune system.
Other studies suggest that micro  biota may 
influence weight gain or loss and adiposity 
in humans. Ley et al. (2006) showed that 
obese humans had a lower Bacteroidetes to 
Firmicutes ratio than lean humans, but that 
this ratio increased with weight loss (Ley et al. 
2006). Armougom et al. (2009) also found 
lower levels of Bacteriodetes in obese persons, 
although Arumugam et al. (2011) found no 
difference in this ratio.
Human studies also indicate weight gain 
during pregnancy can affect gut microbial 
populations and the incidence of obesity in 
offspring (Collado et al. 2008, 2010). Breast- 
versus formula-feeding practices, and vaginal 
versus cesarean section delivery also appear to 
affect the gut ecology of infants and may have 
relevance for obesity (Hallstrom et al. 2004; 
Musso et al. 2010; Penders et al. 2005, 2006). 
Another analysis of human microbiomes sug-
gested that fecal micro  biota composition in 
infants may predict later weight gain in chil-
dren (Kalliomaki et al. 2008).
While debate is ongoing about the rele-
vance of phylum-level differences in obese and 
lean individuals, research in these areas is still 
in its early stages. In order to thoroughly test 
the human adiposity-gut microbe hypothesis, 
additional carefully controlled experiments, 
as well as larger epidemiological studies, are 
needed.
Gut Microbiome and Diabetes
In addition to the growing number of stud-
ies that suggest gut micro  biota may affect the 
development of obesity, several studies suggest 
that the nature of the gut micro  biota is linked 
to type 2 diabetes. This includes a study that 
found men with type 2 diabetes had signifi-
cantly reduced levels of fecal Firmicutes, includ-
ing Clostridia, compared with non-diabetic 
control subjects. Plasma glucose was positively 
correlated with both the ratios of Bacteroidetes 
to Firmicutes, and of the Bacteroides–Prevotella 
group to Clostridium coccoides–Eubacteria rec-
tale group. In addition, the diabetic group 
also had more Beta-proteobacteria than non-
  diabetic controls. The authors suggested that 
the Bacteroidetes and Proteobacteria groups 
may affect diabetes risk via an endotoxin-
  induced inflammatory response, as both are 
gram-  negative bacteria with lipid polysaccharide 
outer membranes (Larsen et al. 2010). Larsen 
et al. (2010) is the first study to show changes 
in microbial populations between type 2 diabet-
ics compared with non-diabetics, but the study 
is based on a small number of subjects (n = 36), 
and these results need to be replicated in larger 
studies. It should also be noted that study sub-
jects in both the diabetic and control groups 
had a wide range of BMIs.Snedeker and Hay
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Other researchers (Membrez et al. 2008) 
have investigated whether gut micro  biota 
affects glycemic control and glucose tolerance 
using animal models of type 2 diabetes. In 
ob/ob mice, a 2-week treatment with anti-
biotics (norfloxacin and ampicillin) decreased 
gut levels of both aerobic and anaerobic bac-
teria. Antibiotic-treated ob/ob mice had sig-
nificantly improved glucose tolerance; this 
was attributed to multiple factors includ-
ing reduced liver triglycerides, increased 
liver glycogen, increased plasma adiponec-
tin, and reduced plasma lipopolysaccarides 
(Membrez et al. 2008). The authors suggested 
that changes in the micro  biota improved glu-
cose tolerance via changes in metabolic and 
inflammatory pathways. Rabot et al. (2010) 
explored whether differences in insulin resis-
tance and glycemic control exist between 
germ-free mice and mice with conventional 
gut microbes. They found that germ-free mice 
fed a high-fat diet consumed fewer calories, 
excreted more fecal lipids, and weighed less 
than conventional high-fat diet–fed mice. The 
germ-free mice also had reduced fasting and 
non-fasting insulinemia and improved glu-
cose tolerance. Rabot et al. (2010) suggested 
these results support a role for gut micro  biota 
in insulin sensitivity.
Relatively few studies have evaluated the 
role of microbes in type 1 diabetes. Vehik and 
Dabelea (2011) suggested that increased gut 
permeability (commonly called “leaky gut”) 
may affect the absorption of antigens that can 
attack and damage pancreatic beta cells. Bosi 
et al. (2006) observed increased gut perme-
ability in human subjects with type 1 diabe-
tes. Because gut microbes can affect intestinal 
permeability (Garcia-Lafuente et al. 2001), 
gut ecology may play a role in the develop-
ment of type 1 diabetes (Neu et al. 2010). 
Another hypothesis by which microbes may 
cause type 1 diabetes is by producing bacterial 
toxins that can directly damage or affect the 
function of pancreatic beta cells. Myers et al. 
(2003) found that injecting the mice with 
Streptomyces toxin, bafilomycin A1, resulted 
in smaller pancreatic beta cells and impaired 
glucose tolerance. This Streptomyces toxin 
can be produced by soil microbes and sub-
sequently infect commonly consumed root 
vegetables such as potatoes. Other microbial 
toxins, such as streptozotocin, have been 
used to induce diabetes in an experimental 
mouse model (Like and Rossini 1976). Little 
is known about other microbial toxins that 
may directly attack pancreatic beta cells and 
affect type 1 diabetes. Kootte et al. (2011) 
have speculated whether manipulating gut 
micro  biota may have therapeutic benefits for 
treating patients with type 2 diabetes, includ-
ing whether prebiotics, postbiotics, antibiotics 
or even microbial transplantation might have 
clinical significance.
Obesogenic and Diabetogenic 
Environmental Chemicals
The possible role of chemical toxins in the 
rising rates of obesity world-wide was first 
proposed by Baillie-Hamilton (2002). Grün 
and Blumberg (2006, 2007) suggested that 
certain environmental pollutants, called 
“obesogens” can disrupt or interfere with the 
body’s homeostatic controls of adipogenesis, 
lipid metabolism, or energy balance. Adipose 
pathways involving nuclear receptors, such as 
the estrogen receptor (ER), retinoid X recep-
tor (RXR), peroxisome proliferator-activated 
receptor-g (PPAR-g), and gluco  corticoid recep-
tors (GR), provided some of the first proposed 
molecular targets of environmental obesogens 
(Grün and Blumberg 2007). Casals-Casas 
and Desvergne (2011) have suggested that 
endocrine-disrupting chemicals that affect adi-
pose and glucose-related pathways should be 
categorized into a subgroup called “metabolic 
disrupting chemicals.” Expanding the obeso-
gen hypothesis, several researchers (Heindel 
and vom Saal 2009; Wolff et al. 2008) have 
proposed that environmental chemicals may 
act during critical windows of prepubertal 
and pubertal development to alter pathways 
involved in food intake, insulin sensitivity, 
lipid metabolism, and adipocyte development.
The level and strength of evidence (human 
vs. experimental animal or cell culture stud-
ies), the mechanism of action, and whether a 
dose–response effect or a low-dose effect (i.e., 
a U-shaped response curve) is observed, all vary 
by chemical. Although relatively few studies 
have examined whether environmental fac-
tors play a role in type 1 diabetes (Howard 
and Lee 2011), associations between the inci-
dence of type 2 diabetes and exposure or use 
of a number of environmental chemicals is 
well supported in the human epidemiologi-
cal literature for dichlorodiphenyldichloro-
ethylene (DDE) (Codru et al. 2007; Cox et al. 
2007; Lee et al. 2006; Rignell-Hydbom et al. 
2009; Son et al. 2010; Turyk et al. 2009a, 
2009b; Ukropec et al. 2010), hexachloroben-
zene (HCB) (Codru et al. 2007; Ukropec 
et al. 2010), highly chlorinated polychlori-
nated biphenyls (PCBs) (Codru et al. 2007; 
Lee et al. 2006, 2010; Ukropec et al. 2010; 
Wang et al. 2008), dioxin (Henriksen et al. 
1997; Kang et al. 2006; Michalek and Pavuk 
2008), chlordane (Cox et al. 2007; Everett and 
Matheson 2010; Lee et al. 2006, 2007a, 2010, 
2011; Son et al. 2010), and occupational expo-
sure to agricultural insecticides and herbicides 
including chlordane, heptachlor, chlorpyrifos, 
diazinon, alachlor, cyanazine, and trichlorofon 
(Montgomery et al. 2008). Without mech-
anisms of action, however, it cannot yet be 
determined if all of the chemicals identified 
play a potential causal role, or if coexposures 
result in detecting some chemicals that do not 
have a biological effect on diabetes risk.
For other chemicals, there is a clearer 
picture of effects in human populations and 
mechanisms of action. Globally, high levels of 
arsenic in water supplies have been associated 
with increased incidence of type 2 diabetes 
(Chen et al. 2007; Navas-Acien et al. 2006; 
Rahman et al. 2009; Tseng 2007). Mechanistic 
studies suggest arsenic may impair insulin 
secretion from pancreatic beta cells and induce 
changes in gene expression affecting pancre-
atic insulin secretion and insulin resistance in 
peripheral tissues (Diaz-Villasenor et al. 2006, 
2007). While a diabetogenic effect of another 
metal, cadmium, was noted in rats exposed 
neonatally (Merali and Singhal 1980), and sug-
gestive evidence on fasting glucose levels in 
humans was reported (Schwartz et al. 2003), 
no mechanism of action has been identified.
Although strong evidence of a mechanism 
of action exists for other chemicals, few if any 
studies have documented whether past or cur-
rent exposure levels in humans pose a risk. 
For example, strong mechanistic data support 
tributyltin as a developmental obesogen, espe-
cially for its action through nuclear receptor 
signaling. PPAR-g is one of the key regulators 
of cell growth and differentiation of adipocytes. 
Tributyltin is an agonist for both PPAR-g and 
the retinoid X receptor (RXR-a, -b and -g) 
(Grün and Blumberg 2006; Grün et al. 2006), 
and tributyltin can sensitize human and mouse 
stromal stem cells to differentiate into adipo-
cytes (Inadera and Shimomura 2005; Kirchner 
et al. 2010). Pubertal exposures in male mice 
cause increased body weight gain, hepatic stea-
tosis, hyperinsulinemia, and hyperleptinemia 
(Zuo et al. 2011). However, the effect of envi-
ronmental tributyltin exposure on related obe-
sity disorders in human populations has not 
yet been investigated. More studies are needed 
to define the extent of human exposure from 
tributyltin’s use in anti-fouling marine paints 
and as a stabilizer in polyvinyl chloride plastics 
as well as its use in wallpaper, textiles, and floor 
coverings (Antizar-Ladislao 2008; Appel 2004; 
Kannan et al. 2010).
As discussed below, for several estrogenic 
environmental chemicals including bisphenol A 
(BPA), alkylphenols nonyl- and octylphenol, 
diethyl  stilbestrol (DES), and genistein, evi-
dence from animal and tissue culture models 
indicate that these environmental estrogens 
affect a variety of other receptor-mediated, cel-
lular, and molecular targets linked to adipose 
and/or glucose metabolism. GR signaling is 
central to adipocyte differentiation. For exam-
ple, using the 3T3-L1 preadipocyte cell line, 
Sargis et al. (2010) demonstrated that BPA 
stimulated GR and increased lipid accumu-
lation in the differentiating adipocytes. BPA 
can also modulate glucose transport in mouse 
3Y3-F442A adipocytes, enhancing the level 
of a key glucose transport protein GLUT4 
(Sakurai et al. 2004). Other studies have shown Obesity/diabetes: gut ecology–chemical connections
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that BPA can suppress the release of adiponec-
tin (which can affect insulin sensitivity and 
resistance) from human adipocytes or adipose 
explants (Hugo et al. 2008).
Evidence from animal studies on the effects 
of early-life BPA exposure on obesity is not 
consistent; effects appear to depend on route 
of exposure, sex, and species (Miyawaki et al. 
2007; Rubin et al. 2001; Ryan et al. 2010). 
Human studies have not provided strong evi-
dence of an effect on obesity for current levels 
of human BPA exposure (Lang et al. 2008; 
Melzer et al. 2010).
Using 3T3-L1 adipocytes, researchers 
have found that the alkylphenols octyl  phenol 
and nonylphenol up-regulate the expression 
of the resisten gene, which affects insulin 
resistance and decreases adipocyte differentia-
tion. Male rats treated with octylphenol show 
increased serum levels of glucose (Lee et al. 
2008). Although nonylphenol has been widely 
detected in human adipose tissue, a positive 
relationship between the measures of obe-
sity such as BMI and adipose levels for this 
environmental estrogen has not been shown 
(Lopez-Espinosa et al. 2009).
Neonatal exposure of mice to the non-
steroidal estrogen DES results in an initial 
weight loss followed by an increase in body 
fat by 2 months of age (Newbold 2010). 
DES exposure increases serum leptin and 
triglycerides levels and changes the expres-
sion of several genes involved in fat distribu-
tion (Newbold et al. 2007). Cohort studies 
have not yet determined whether there is a 
higher incidence of obesity in DES mothers, 
or in their children exposed to DES in utero, 
even though this compound has been found 
to have multi  generational effects on other end 
points such as female cervical cancer and male 
urogenital malformations (Palmer et al. 2009; 
Troisi et al. 2007).
For the phytoestrogen genistein, effects 
on gene expression of adipose-related factors, 
including induction of phospholipase A2 
group 7 and phospholipid transfer protein 
genes, were seen at low, but not high, doses 
in a mouse study (Penza et al. 2006). This 
suggests that for some environmental chemi-
cals, especially those with hormonal action, 
low-dose effects need to be examined rather 
than relying on traditional high-dose response 
effects. U-shaped response curves have been 
reported for other environmental chemicals, 
including some congeners of polybrominated 
  diphenyl ether (PBDE) flame retardants 
including PBDE-153, and certain PCBs (Lee 
et al. 2007b, 2011; Lim et al. 2008). The 
U-shaped response curves suggest that future 
research is needed to determine if other chem-
icals have low-dose effects on metabolic syn-
drome, obesity, and diabetes.
The effects of individual chemicals on 
obesity and diabetes cannot be generalized 
to entire classes of chemicals. For instance, 
type 2 diabetes–related effects of PCBs and 
brominated flame retardants [polybrominated 
biphenyls (PBBs), and PBDEs] appear to be 
more closely associated with highly haloge-
nated forms of these chemicals (Everett et al. 
2007; Lee et al. 2010; Lim et al. 2008). Only 
certain types or metabolites of phthalates 
appear to be associated with obesity or diabe-
tes in humans (Hatch et al. 2008). In rodent 
studies, diisobutylphthalate shows some evi-
dence of affecting obesity via PPAR pathways 
(Boberg et al. 2008), but evidence for other 
phthalates, including diethylhexyl phthalate, is 
less consistent (Casals-Casas et al. 2008; Feige 
et al. 2010).
For other chemicals such as the PPAR ago-
nist perfluorooctanoic acid (PFOA), evidence 
of an association with obesity and diabetes is 
emerging but inconsistent. Although there is 
some evidence of a higher incidence of diabe-
tes in persons who are occupationally exposed 
to PFOA (Lundin et al. 2009), a large-scale 
cross-sectional epidemiological study did not 
observe a relationship between PFOA levels 
and type 2 diabetes or fasting glucose levels 
(MacNeil et al. 2009). Rodent studies indicate 
that PFOA can be transmitted from the dam 
to pup during lactation (Fenton et al. 2009), 
and there is some evidence of PFOA being a 
developmental obesogen in mice (Hines et al. 
2009), but studies in rats have not indicated an 
effect of early-life PFOA exposure on plasma 
insulin or leptin levels (Boberg et al. 2008).
Disposition of Environmental 
Chemicals
In addition to the host–microbe interac-
tions and the direct effects of the chemicals 
discussed above, we suggest that microbes 
may affect obesity and diabetes by altering 
the ADME of environmental chemicals. 
Microbially mediated effects on ADME could 
include the direct activation of chemicals (Van 
de Wiele et al. 2005, 2010; Wallace et al. 
2010), production of microbial metabolites 
that compete for limited host biotransforma-
tion capacity (Clayton et al. 2009; Wallace 
et al. 2010), alteration of host biotransfor-
mation enzyme activities (Claus et al. 2011; 
Meinl et al. 2009), changes in enterohepatic 
circulation (Meijer et al. 2006), or altered bio-
availability of environmental chemicals and/
or antioxidants from food (Kemperman et al. 
2010; Lhoste et al. 2003; Oishi et al. 2008; 
van Duynhoven et al. 2010). Increased bio-
availability may also result from changes in 
gut motility and barrier function. Although 
evidence indicates that the ADME of environ-
mental chemicals may be affected by many of 
these microbial-mediated pathways, no studies 
have evaluated how the ADME of obesogenic 
or diabetogenic chemicals are affected by varia-
tions in the human microbiome. Thus, there is 
a need to determine the effect of microbes on 
the bioavailability of environmental chemicals, 
and the direct biotransformation of persis-
tent organic pollutants (Dean and Ma 2007; 
Possemiers et al. 2009).
Using an in vitro model that simulates 
the human intestinal microbial system (biota 
cultured from human feces), Van de Wiele 
et al. (2005) demonstrated that colonic micro-
biota were capable of transforming polyaro-
matic hydrocarbons (PAHs) to the bioactive 
estrogenic metabolites 1-hydroxy  pyrene and 
7-hydroxybenzo[a]pyrene, whereas stomach 
and small intestine digests of the PAH did not 
produce estrogenic metabolites. This finding 
suggests that colonic microbes can biotrans-
form parent compounds directly into active 
metabolites. Gut microbes were found to thi-
olate and methylate arsenic in both human 
and mouse models (Pinyayev et al. 2011; Van 
de Wiele et al. 2010). Exposure to high levels 
of arsenic have been associated with both an 
increased risk of bladder cancer and a higher 
incidence of diabetes in persons living in areas 
with contaminated water supplies and/or sea-
food (Chen et al. 2007; Coronado-Gonzalez 
et al. 2007; Kim and Lee 2011; Navas-Acien 
et al. 2006; Rahman et al. 2009; Yen et al. 
2007). Although these microbial model systems 
suggest the capacity for biotransformation of 
environmental chemicals in the gut, especially 
the colon, their impact on systemic pollutant 
levels is not known. The extent of biotransfor-
mation variation by the gut microbes, so called 
“presystemic metabolism” (Grundmann 2010) 
of different individuals is also not known. 
Despite phylogenetic diversity, the implied 
functional metabolic redundancy observed 
in the gut metagenomes of individual twins 
(Turnbaugh et al. 2009a) raises the question as 
to whether or not important differences exist 
between the enzymatic capacities of individuals. 
Although no large-scale functional studies have 
been done to characterize the interindividual 
variation in gut microbe enzymatic capacity, 
the available human and rodent data suggest 
that variations in gut micro  biota affect envi-
ronmental chemical disposition (McBain and 
MacFarlane 1998; Rowland et al. 1985). This 
has been indirectly established in the area of 
colon cancer where variation in fecal enzyme 
activities has been found to correlate with can-
cer risk (Rowland 2009). 
The pharmacology literature provides valu-
able evidence demonstrating how chemical 
fate can be affected by variability in the host 
microbiome (Clayton et al. 2009; Sousa et al. 
2008; Wallace et al. 2010; Wilson 2009). For 
example, a 2008 review identified 30 drugs 
(including chloramphenicol) that can be 
metabolized by gut micro  biota whose metabo-
lism shows considerable interindiviual vari-
ability depending on the presence or absence 
of specific bacteria genera (Sousa et al. 2008). Snedeker and Hay
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In addition, studies have shown that variations 
in gut micro  biota can affect the metabolism 
of commonly used over-the-counter drugs 
such as acetaminophen (Clayton et al. 2009) 
and that limiting gut microbial metabolism of 
chemotherapy drugs can reduce drug toxicity 
(Wallace et al. 2010).
Recent evidence suggests that acetamino-
phen’s metabolism and toxicity are affected 
by individual variations in the gut micro-
biome (Clayton et al. 2009). Some gut bacte-
ria, including Clostridium difficle, metabolize 
tyrosine to p-cresol, which can compete with 
acetaminophen for sulfonation in the gut. 
In individuals whose gut bacteria produce 
high levels of p-cresol, less acetaminophen 
undergoes sulfonation because of competi-
tion with p-cresol and more is glucuronidated. 
Researchers found that the ratio of sulfonated 
to glucuronidated p-cresol in the urine was 
predictive of acetaminophen toxicity. The 
same markers are likely relevant to metabolism 
of other compounds that rely on these path-
ways for detoxification (Clayton et al. 2009), 
including many that have been suggested to 
be environmental obesogens or diabetogens 
[see Supplemental Material, Table 1 (http://
dx.doi.org/10.1289/ehp.1104204)].
Another example of gut ecology– 
pharmaceutical interaction is the metabolism 
of the chemotherapeutic prodrug CPT-11. 
Upon administration, CPT-11 is first acti-
vated by carboxyesterases in the liver to yield 
toxic SN38, which in turn is glucuroni-
dated by uridine diphosphate (UDP)-
glucuronosyltransferase to nontoxic SN38G. 
SN38G is excreted into the bile and returned 
to the gut where b-glucuronidases from com-
mensal gut bacteria remove the glucuronide. 
This reactivates the drug in the gut, which can 
in turn cause bloody diarrhea, limiting the 
dose that can be used in chemo  therapy. To 
circumvent the unintended intestinal toxicity 
of SN38, researchers developed an inhibitor of 
microbial glucuronidase that was not toxic to 
gut microbes, but which prevented the metab-
olism of SN38G and thereby increased mouse 
tolerance to CPT-11 (Wallace et al. 2010). 
Microbial glucuronidase activity also has been 
shown to be important in activating food-
borne procarcinogens in the gut (Humblot 
et al. 2007), further illustrating the role of this 
enzyme in chemical metabolism.
The above examples underscore the rea-
sons recent reviews in the pharmacology lit-
erature have articulated the need for future 
drug development to include an integrated 
assessment of host and environmental fac-
tors, including gut microbes that affect drug 
disposition (Grundmann 2010; Sousa et al. 
2008; Wilson 2009; Wilson and Nicholson 
2009). This topic has received little attention 
in the toxicology literature (Possemiers et al. 
2009). In this regard, pharmaco  metabolomics 
appears to be an important emerging tool 
for investigating how gut ecology may affect 
the fate of chemical toxicants and their con-
tribution to diabetes and obesity risk. Given 
the established functional differences in the 
microbiomes of obese and lean humans 
(Arumugam et al. 2011), microbes may be an 
important source of variation in the ADME 
profile of obesogenic and diabetogenic chemi-
cals and deserve increased attention.
This is especially important in light of evi-
dence in animal models that suggest changes 
in gut micro  biota not only affect levels of 
gut metabolic enzymes, but levels of hepatic 
enzymes as well (Claus et al. 2011; Meinl et al. 
2009; Reddy et al. 1973). The ability of gut 
micro  biota to affect levels of hepatic enzymes 
was initially demonstrated for carbohydrate-
metabolizing enzymes. Compared with 
germ-free rats, conventional rats displayed a 
significantly higher activity of hepatic glucose-
6-phosphate dehydrogenase (Reddy et al. 
1973). Limited recent evidence indicates that 
certain phase I enzymes also can be influenced 
by gut micro  biota. The expression and level of 
P450 enzymes Cyp3a11 and Cyp2c29 were 
significantly higher in the livers of mice with 
conventional gut micro  biota compared with 
germ-free control mice (Claus et al. 2011).
Several hepatic and gut phase II enzymes 
also have been compared in germ-free and 
germ-free rats “reassociated” with conventional 
micro  biota (Meinl et al. 2009). These include 
glutathione transferases, glutathione peroxi-
dase, epoxide hydrolases, acetyltransferases, 
and sulfotransferases. Levels of isoenzymes 
were compared in the liver, small intestine, 
cecum, and colon of germ-free and reassoci-
ated control rats. In most cases, germ-free rats 
had higher levels of colonic phase I and II 
enzymes than control rats with conventional 
micro  biota, although there was no effect of 
germ-free status on the levels of enzymes in 
the small intestine. Differences were, how-
ever, observed in the level of liver enzymes 
in germ-free rats compared with reassociated 
rats of both sexes, with elevations in sulfo-
transferases. Hepatic epoxide hydrolase was 
elevated in germ-free rats as well, but only in 
females (Meinl et al. 2009).
Levels of hepatic biotransformation 
enzymes can also be affected by diet-induced 
changes in gut microbes (Treptow-van 
Lishaut et al. 1999). Levels of glutathione 
S-transferase-p (the predominant GST isoen-
zyme) were lower in colon cells of germ-free 
rats compared with colon cells of rats with con-
ventional micro  biota. The levels of this enzyme 
increased 3-fold when the diet of rats with 
conventional micro  biota was changed from 
a highly digestible maize starch to a poorly 
digestible high-amylose maize starch. The 
authors suggested that amylose was fermented 
in the colon, and may have yielded short-chain 
fatty acids such as n-butyrate, which may have 
induced GST (Treptow-van Lishaut et al. 
1999). Changes in gut micro  biota composition 
were not measured with the dietary change, so 
it is unknown to what extent gut micro  biota 
may have affected induction of GST directly; 
however, this report does suggest that changes 
in gut microbial activity (fermentation) cor-
relate with changes in this phase II enzyme that 
plays an important role in cellular detoxifica-
tion (Di Pietro et al. 2010). The potential for 
diet/microbe-enhanced induction of detoxifi-
cation capacity demonstrated in the colon of 
animal models contributes to interest in the 
potential detoxification and anticancer effects 
of both pre- and probiotics; however, further 
human studies are required (Genuis 2011).
Some evidence from laboratory animal 
studies indicates that the polyphenols quer-
cetin and catechin may influence liver or gut 
levels of phase II enzymes (Lhoste et al. 2003; 
Wiegand et al. 2009) and that gut microbes 
play a role in polyphenol-mediated enzyme 
induction (Lhoste et al. 2003). Few studies 
have looked at the levels or activity of phase II 
biotransformation enzymes in the human gut 
(Peters et al. 1991; Teubner et al. 2007). Little 
is known concerning to what extent activi-
ties of these biotransformation enzymes are 
affected by the wide variations in the human 
microbiome. Hence, we have virtually no 
information on how variations in gut ecology 
affect human ADME capacity with respect to 
environmental chemicals. Understanding how 
other dietary components, including poly-
phenols, might modify gut microbial popula-
tions and levels of phase I and II enzymes, 
may yield important information relevant to 
interindividual variation in chemical metabo-
lism (Kemperman et al. 2010; van Duynhoven 
et al. 2010).
Another area where little information exists 
is whether the enterohepatic circulation of envi-
ronmental chemicals is affected by variation in 
gut microbial populations. Since many envi-
ronmental toxicants undergo phase II metab-
olism [see Supplemental Material, Table 1 
(http://dx.doi.org/10.1289/ehp.1104204)], 
those that are excreted in the bile may be fur-
ther metabolized by the enzymes of gut micro-
biota, including glucuronidases, leading to 
enterohepatic circulation and increased resi-
dence time in the body (Humblot et al. 2007). 
The importance of this process has been dem-
onstrated by administration of nonabsorbable 
fat (i.e., sucrose polyester), which decreases 
enterohepatic circulation and increases fecal 
fat excretion of the flame retardant PBDE-47 
(Meijer et al. 2006). To what extent enterohe-
patic circulation of lipophillic persistent pol-
lutants, including obesogenic or diabetogenic 
chemicals, can be influenced by variations in 
gut microbial populations is unclear; however, 
the limited information available suggests that Obesity/diabetes: gut ecology–chemical connections
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the variability in the activity levels of relevant 
gut microbe enzymes may be quite high, espe-
cially for b-glucuroronidase (Rowland et al. 
1986). Given the importance of microbial 
b-glucuronidases in enterohepatic cycling, and 
the enrichment of related genes (e.g., those 
encoding hydrolases) in obesity-associated 
microbiomes (Turnbaugh et al. 2009a), it is 
important that we understand interindividual 
differences in enterohepatic cycling and how 
they may affect the risk of obesity or diabetes.
Conclusions and Future 
Research Needs
Microbial populations and/or metabolic 
capacities are known to differ in obese and 
lean subjects (and in type 2 diabetes), yet 
we know surprisingly little about the effect 
of these differences on the body burden of 
obesogenic and diabetogenic chemicals. The 
ability to characterize and manipulate micro-
bial populations in gnotobiotic mice, how-
ever, including humanizing of the rodent gut 
(Goodman and Gordon 2010), provide us 
with an unparalleled opportunity to begin 
exploring the impact of gut microbe variability 
on the disposition of environmental chemicals 
in humans. Future research in this area should 
quantify how interindividual variations in gut 
micro  biota affect the body burden of environ-
mental chemicals by altering a) these chemicals 
directly, b) the level and activity of host phase I 
and II enzymes, c) enterohepatic circulation of 
environmental chemicals, d) depletion of host 
detoxification capacity, and e) alterations of 
gut barrier function. Studies should also iden-
tify biomarkers that are predictive of impaired 
obesogenic and diabetogenic chemical absorp-
tion, distribution, metabolism, and excretion 
and assess the interaction between micro  biota 
and developmental obesogens, including inter-
generational effects. This approach will shed 
light on how variations in gut ecology affect 
the metabolism of obesogenic and diabeto-
genic chemicals and lead to more personalized 
approaches in the treatment and prevention of 
obesity and diabetes.
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